Table 3 Comparison of clinical treatment between NSTEMI patients during non-COVID-19 and COVID-19 pandemic periods
From: Reconsidering treatment guidelines for acute myocardial infarction during the COVID-19 pandemic
| Â | NSTEMI | p-value | |
|---|---|---|---|
Group 1 (n = 101) | Group 2 (n = 43) | ||
Treatment place, n (%) | Â | Â | 0.001* |
 Accident and emergency department | 9 (8.9) | 13 (30.2) |  |
 In-hospital | 92 (91.1) | 30 (69.8) |  |
Reperfusion therapy, n (%) | 71 (70.3) | 16 (37.2) |  < 0.001* |
 PCI within 24 h in-hospital | 18 (17.8) | 9 (20.9) | 0.662 |
 PCI after 24 h in-hospital | 44 (43.6) | 7 (16.3) | 0.002* |
 CABG | 9 (8.9) | 0 (0.0) | 0.100 |
Conservative therapy, n (%) | 30 (29.7) | 27 (62.8) |  < 0.001* |
FMC time (min), median (IQR) | 236.0 (106.0,675.0) | 412.0 (181.0,839.0) | 0.036* |